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ABSTRACT
Fasting in the Islamic month of Ramadan is
obligatory for all sane, healthy adult Muslims.
The length of the day varies significantly in
temperate regions—typically lasting C 18 h
during peak summer in the UK. The synodic
nature of the Islamic calendar means that
Ramadan migrates across all four seasons over
an approximately 33-year cycle. Despite valid
exemptions, there is an intense desire to fast
during this month, even among those who are
considered to be at high risk, including many
individuals with diabetes mellitus. In this
review we explore the current scientific and
clinical evidence on fasting in patients with
diabetes mellitus, focussing on type 2 diabetes
mellitus and type 1 diabetes mellitus, with brief
reviews on pregnancy, pancreatic diabetes, bar-
iatric surgery, the elderly population and cur-
rent practice guidelines. We also make
recommendations on the management of dia-
betes patients during the month of Ramadan.
Digital Features To view digital features for this article
go to https://doi.org/10.6084/m9.figshare.12624905.
Electronic Supplementary Material The online
version of this article (https://doi.org/10.1007/s13300-
020-00886-y) contains supplementary material, which is
available to authorized users.
S. H. Ahmed (&)  S. T. Seal
Department of Endocrinology and Metabolic
Medicine, Countess of Chester Hospital NHS
Foundation Trust, Chester, UK
e-mail: asyedharis76@gmail.com
S. H. Ahmed
School of Medicine, University of Liverpool,
Liverpool, UK
T. A. Chowdhury
Department of Diabetes and Metabolism, Royal
London Hospital, London, UK
S. Hussain  A. Hodgkinson
Department of Diabetes and Endocrinology, Guy’s
& St Thomas’ NHS Foundation Trust, London, UK
S. Hussain
Department of Diabetes, School of Life Course
Sciences, King’s College London, London, UK
S. Hussain
Institute of Diabetes, Endocrinology and Obesity,
King’s Health Partners, London, UK
A. Syed  A. Karamat  A. Helmy
Department of Diabetes and Endocrinology,
University Hospitals Birmingham NHS Foundation
Trust, Birmingham, UK
S. Waqar
Nuffield Department of Primary Care Health
Sciences, University Oxford, Oxford, UK
S. Ali
NHS Greater Glasgow and Clyde, Glasgow, UK
A. Dabhad
Royal Wolverhampton NHS Trust, Wolverhampton,
UK
Diabetes Ther
https://doi.org/10.1007/s13300-020-00886-y
Many patients admit to a do-it-yourself
approach to diabetes mellitus management
during Ramadan, largely due to an under-ap-
preciation of the risks and implications of the
rigors of fasting on their health. Part of the issue
may also lie with a healthcare professional’s
perceived inability to grasp the religious sensi-
tivities of Muslims in relation to disease man-
agement. Thus, the pre-Ramadan assessment is
crucial to ensure a safe Ramadan experience.
Diabetes patients can be risk-stratified from low,
medium to high or very high risk during the
pre-Ramadan assessment and counselled
accordingly. Those who are assessed to be at
high to very high risk are advised not to fast.
The current COVID-19 pandemic upgrades
those in the high-risk category to very high risk;
hence a significant number of diabetes patients
may fall under the penumbra of the ‘not to fast’
advisory. We recognize that fasting is a personal
choice and if a person chooses to fast despite
advice to the contrary, he/she should be ade-
quately supported and monitored closely dur-
ing Ramadan and for a brief period thereafter.
Current advancements in insulin delivery and
glucose monitoring technologies are useful
adjuncts to strategies for supporting type 1
diabetes patients considered to be high risk as
well as ‘high-risk’ type 2 patients manage their
diabetes during Ramadan. Although there is a
lack of formal trial data, there is sufficient evi-
dence across the different classes of therapeutic
hypoglycaemic agents in terms of safety and
efficacy to enable informed decision-making
and provide a breadth of therapeutic options for
the patient and the healthcare professional,
even if the professional advice is to abstain.
Thus, Ramadan provides an excellent opportu-
nity for patient engagement to discuss impor-
tant aspects of management, to improve control
in the short term during Ramadan and to help
the observants understand that the metabolic
gains achieved during Ramadan are also sus-
tainable in the other months of the year by
maintaining a dietary and behavioural disci-
pline. The application of this understanding
can potentially prevent long-term
complications.
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Key Summary Points
Fasting in Ramadan is obligatory for all
adult, healthy and sane Muslims.
There are proven metabolic benefits of
Ramadan fasting in healthy as well as
diabetes patients.
Given the propensity of acute metabolic
derangements and medicine-related side-
effects, patients with diabetes can be at
significant health risk by fasting.
A pre-Ramadan risk stratification is crucial
for diabetes patients, to guide and support
the patients with informed decision-
making.
High- to very high-risk patients are
advised not to fast but if they choose to
fast, they should be supported and
monitored closely.
Pre-Ramadan assessment and education
have been shown to improve the fasting
experience of patients with diabetes.
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There is emerging evidence that newer
technologies, such as insulin pump
therapy, continuous glucose monitoring
and hybrid closed-loop systems, can help
type 1 diabetes patients and some
evidence that flash glucose monitoring
can help high-risk type 2
diabetes patients, fast with fewer
complications.
In the current pandemic, patients in the
low- or moderate-risk category, who are
exposed to patients with confirmed
COVID-19, are safe to fast as long as they
are asymptomatic. Those who develop
symptoms whilst fasting should be
advised to break the fast.
INTRODUCTION
Fasting in the Islamic month of Ramadan is
obligatory for all sane, healthy adult Muslims.
Muslims refrain from eating, drinking and
conjugal relations between dawn and sunset for
29–30 days during Ramadan, the ninth month
of the Muslim lunar calendar. The synodic
nature of the Muslin calendar means that
Ramadan occurs 10–11 days earlier each Gre-
gorian year, migrating across all four seasons
over an approximately 33-year cycle. The
length of the day varies significantly in tem-
perate regions—typically lasting C 18 h during
peak summer in the UK [1].
As a general rule, a person observing fasting
is not allowed any form of nutrition (including
via a percutaneous endoscopic gastrostomy
tube) and medication that involves adminis-
tration via a mucosal route (i.e. oral, nasal or
rectal). The use of topical, intramuscular and
subcutaneous medications, such as insulin, is
permitted and does not invalidate the fast [2]. It
is traditional practice to have two meals over
the 24-h period—Suhoor (also known as Sehri),
the pre-dawn meal, and Iftaar, the sunset meal.
Fasting is associated with beneficial changes to a
person’s general wellbeing [3].
Ultimately thedecision to fastorotherwise rests
with the individual concerned. Islam permits, and
indeed supports, those with appropriate ailments
to terminate the fast or be exempted from fasting,
the twomain options being:
• Making up the missed fast when health
permits them to do so—either when the
illness is no longer present, such as in acute
illness, or when health is not worsened by
fasting at another point in time (e.g. in the
winter), in relation to chronic illness [1].
• An exemption from fasting in those whose
illness will not permit them to keeping fasts
indefinitely, this being replaced by a require-
ment to feed the poor.
Appropriate ailments that enable the above
exemptions can also include old age or a condi-
tion which is stable, but which through fasting
can adversely affect health or increase the risk of
doing so [1, 4]. This also includes abstaining from
the use of medication that increases the risk of
decompensation of chronic, but stable health
conditions. Arriving at such decisions is based on
the premise that the ailment will worsen, or
recovery will be delayed or impaired by fasting, or
a substantial fear that either may occur, which in
turn can be determined by prior experience of
fasting with the ailment, on common knowledge
that this can happen or on the advice/opinion of
an appropriate healthcare professional (HCP) [5].
Similarly, pregnant and breastfeeding mothers
have the option to abstain from fasting if there is
any concern for, or risk to, mother or baby.
Muslims are encouraged, if they have any uncer-
tainty regarding the various dispensations, to seek
counsel from a religious authority.
Despite valid exemptions, there is an intense
desire to fast during this month even among
those who are considered to be at high risk, such
as the elderly and multimorbid, including indi-
viduals with diabetes mellitus (DM) [6, 7]. Dia-
betes is classified into various forms of diabetes.
These include the more common forms, such as
type 2 (T2) diabetes, with its wide-ranging spec-
trums, type 1 (T1) diabetes, diabetes during
pregnancy and gestational diabetes and pancre-
atic diabetes, and the less common forms, such
as cystic fibrosis-related diabetes and maturity
onset diabetes of the young (MODY). DM is a
classic example of a condition in which indi-
viduals can be on a spectrum of disease severity,
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which would imply that there would be a spec-
trum of risk from fasting. Therefore, the religious
and clinical advice being offered will have to be
individualized and dependent on a multifacto-
rial assessment of the patient. In this review we
explore the current scientific and clinical evi-
dence on fasting in patients with diabetes,
focusing on T2 diabetes, T1 diabetes and guid-
ance on pregnancy and pancreatic diabetes, as
well as current practical guidelines. We also
make recommendations on the management of
diabetes patients during the month of Ramadan.
This article is based on previously conducted
studies and does not contain any studies with
human participants or animals performed by
any of the authors.
METHODS
We undertook a narrative review of current litera-
ture on fasting during Ramadan for patients with
diabetes. We performed a literature search of vari-
ous databeses, including PubMed, Google Scholar,
CiNAHL, among others using the search terms
‘‘diabetes’’, ‘‘type 2 diabetes’’, ‘‘Ramadan’’ and
‘‘fasting’’ in various combinations. A number of
publicationswere retrieved, covering the spectrum
fromobservational studies, randomizedcontrolled
trials (RCT), systematic, non-systematic and the-
matic reviews to practice and management guide-
lines published by group of authors with a
renownedpublicationhistoryon this topic.Whilst
the majority of research and focus in this review
relates to T2 diabetes, other forms of diabetes,
including T1 diabetes, are briefly discussed.
PHYSIOLOGY
AND PATHOPHYSIOLOGY
OF FASTING AND THE EFFECTS
OF RAMADAN FASTING
IN HEALTHY INDIVIDUALS
Normal Physiology
In healthy individuals, the insulin level rises in
response to blood glucose levels, leading to glu-
cose disposal by glycogen synthesis in the liver
and muscle and inhibition of glycogenolysis and
gluconeogenesis (Fig. 1). Within the first few
hours of fasting, as glucose levels fall, insulin
secretion is suppressed. When the plasma glucose
levels fall below the physiological range (3.6–-
3.9 mmol/L [65–70 mg/dL]), the counterregula-
tory hormones glucagon and epinephrine are
secreted. Hepatic glycogenolysis stimulated by
glucagon and epinephrine serves to maintain
blood glucose level within the physiological
range. As fasting progresses, with a progressive
rise in glucagon and epinephrine, glucose meta-
bolism switches to a combination of glycogenol-
ysis and gluconeogenesis whereby de novo
glucose is synthesized from glycerol and amino
acid residues. It takes about 12–36 h for the hep-
atic glycogen levels to be depleted, following
which fatty acids from the adipose tissue are
mobilized to form ketone bodies which serve as
fuel for vital organ function, preserving glucose
for utilization by the brain and erythrocytes
(Fig. 2).
Typically, after 12–36 h of fasting, when liver
glycogen stores are depleted, a metabolic switch
occurs, resulting in lipolysis and the production
of free fatty acids and glycerol. Free fatty acids
released into the blood stream undergo beta-
oxidation in the liver to produce the ketones,
beta-hydroxybutyrate (b-OHB) and acetoac-
etate. These are utilized by the brain, muscle
cells other tissues for energy and serve to pre-
serve lean muscle mass, improve body compo-
sition, optimize physiological function and
slow ageing and disease processes [8].
Altered Physiology of Fasting in Diabetes
Depending on the subtype of diabetes, there are
varying degrees of defects in insulin and gluca-
gon secretion and insulin resistance, with the
potential for serious glycaemic consequences
(Fig. 3). For those with T2 diabetes at the less
severe end of the spectrum, primary defects are
in insulin resistance; however, with disease
progression in the form of beta-cell failure and
greater insulin deficiency, a phenotype closer to
T1 diabetes may become more apparent [9].
Insulin resistance prolongs the time to ‘‘flip the
metabolic switch’’, which implies that it may
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take longer to generate fatty acid for energy and
other metabolic benefits [8]. In early T2 dia-
betes, fasting or very low calorie diets and con-
trolled fasting associated with modest weight
loss can have favourable effects on the early
pathophysiological components of insulin
resistance and adiposity and normalize blood
sugars, i.e. reverse the T2 diabetes phenotype
[10, 11].
However, in potentially very advanced forms
of T2 diabetes and, more importantly, in T1
diabetes patients, due to absolute insulin defi-
ciency, there is a theoretical risk of clinically
significant ketogenesis and significant hyper-
glycaemia in the absence of exogenous insulin.
In addition to this, impaired counterregulatory
responses to hypoglycaemia along with the
inability to decrease circulating insulin of
exogenous origin and reduction in the adrenal
and sympathetic neural tone, there is potential
for severe hypoglycaemia [12]. In patients with
poor control manifested by chronic
hyperglycaemia, the plasma threshold for the
secretion of counterregulatory hormones is
elevated and is the converse of that in patients
with recurrent hypoglycaemia, for example in
patients who maintain tight diabetes control
[13, 14]. Hyperglucagonaemia in T2 diabetes is a
well-recognized contributor to hyperglycaemia
by stimulating increased hepatic production,
but the risk of ketoacidosis is low due to the
relative presence of insulin [15, 16]. The effects
of intermittent fasting on glucagon levels in T2
diabetes have not been formally studied.
A study on 56 patients using continuous
glucose monitoring (CGM), of which 50
patients had T2 diabetes and 6 had T1 diabetes,
compared the profiles using the combined
dataset between Ramadan and non-Ramadan
periods and found statistically significant dif-
ferences in variability at different time points in
mean glucose profiles, over a 24-h period
(Fig. 4). A rapid rise in glucose was observed
after Iftaar, which could be explained by the
Fig. 1 Physiology of glucose metabolism in the fed state
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high glycaemic index and quantity of the meal,
timing of intake of the diabetes medications
(taken just before or after a meal) and hormonal
changes from prolonged fasting [17].
METABOLIC EFFECTS
OF CONTROLLED AND RAMADAN
FASTING
A wide range of metabolic benefits from Rama-
dan fasting has been described in the literature.
The eating pattern during Ramadan fasting
conforms to the definition of time restricted
feeding (TRF), which is one form of intermittent
fasting [8]. Intermittent fasting can be a means
of ‘‘flipping the metabolic switch’’ that can serve
to preserve lean muscle mass, improve body
composition, optimize physiological function
and slow ageing and disease processes [8]. A
study of TRF in overweight humans showed up
to a 4% weight loss over 16 weeks that was
sustained for[1 year and improvement in sleep
pattern and daytime alertness [18].
Studies have shown that in the final week of
Ramadan there is a reduced rate of oxygen
consumption [19, 20] and lower resting heart
rate [20, 21], indicating a slowing of metabo-
lism. There is also reduced submaximal exercise
oxygen consumption [21, 22] and heart rate
Fig. 2 Physiology of fasting in a healthy individual. b-OHB Beta-hydroxybutyrate
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[23]. Fuel selection at rest [19] and during sub-
maximal exercise favours lipid oxidation [23].
Ramadan fasting has been shown to induce a
significant reduction in fat percentage in over-
weight and obese people [24], leading to weight
loss [24, 25]. Weight loss is more significant in
those who fast throughout Ramadan [26]. Fur-
thermore, a cross-sectional study investigating
the impact of Ramadan fasting on inflamma-
tory cytokines, immune biomarkers and
anthropometric measurements has shown a
significant reduction in interleukin 1b, inter-
leukin-6, tumour necrosis factor alpha, systolic
and diastolic blood pressures, body weight and
body fat percentage (at the end of the third
week of Ramadan) [27].
There is growing evidence that short-term
fasting can improve patient response to cancer
chemotherapy, whilst providing protection
from toxicity [28].
Habbal et al. studied the variations in blood
pressure during the month of Ramadan in a
small cohort and found that the variations are
minimal [29]. Perk et al. found no change in
ambulatory blood pressure before [30] and
during Ramadan, while Ural et al. found no
statistically significant difference between 24-h
blood pressure monitoring of hypertensive
Fig. 3 Pathophysiology of fasting in diabetes patients. IF intermittent fasting, IR insulin resistance, T1DM type 1 diabetes
mellitus, T2DM type 2 diabetes mellitus
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patients on combination drug therapy during
and 1 month after Ramadan [31].
One study reported a lower adiponectin
level, elevated morning leptin levels and low-
ered evening growth hormone levels in Rama-
dan practitioners in Saudi Arabia [32]. Higher
adiponectin levels are associated with improved
insulin sensitivity. Conversely, another study
showed increase in adiponectin at the end of
Ramadan [33]. These changes may be due to
changes in meal and sleeping patterns during
Ramadan. There have been no studies looking
at these levels in fasting diabetes patients, thus
no meaningful conclusions can be drawn.
Finally, the effect of the changes in the sleep
pattern as dictated by the timing of the Suhoor
meal or dawn meal have been studied. Typi-
cally, Muslims wake up between 0200 and 0600
hours for the meal, depending on the geo-
graphical latitude and time of the year. After the
meal they may go back to sleep or remain
awake. There is possible decreased total sleep
time (particularly if an afternoon or evening
nap is not had), delayed sleep onset and
decreased proportion of rapid eye movement
(REM) sleep. There is a known medical correla-
tion between sleep duration and insulin resis-
tance. Circadian patterns of hormonal secretion
that are generally sleep-entrenched are altered
due to changes in the sleeping and eating pat-
terns as well as by fasting. One study showed an
inversion of the cortisol secretion pattern with
lower morning cortisol and higher evening
cortisol levels by day 7 of Ramadan, reverting to
near baseline by day 21 (Fig. 5) [34].
EPIDEMIOLOGICAL
OBSERVATIONAL DATA
OF DIABETES MELLITUS
AND RAMADAN, AND LANDMARK
STUDIES
The estimated global prevalence of diabetes as
of 2019 is approximately 463 million adults,
Fig. 4 Mean 24-h continuous glucose monitoring (CGM)
profiles derived from all patients with diabetes (n = 56)
during Ramadan (Fasting) and non-Ramadan (Non-fasting)
periods. The purple bars along the x-axis at the bottom of the
graph depict periods when the difference between the two
states is large and significant*Reprinted fromDiabetesMetab,
Vol 41, Lessan et al, Glucose excursions and glycaemic control
during Ramadan fasting in diabetic patients: Insights from
continuous glucose monitoring (CGM), pp28–36, Copy-
right (2015), with permission from Elsevier [17]
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which is expected to rise to 700 million by 2045
[35]. India, Egypt, Indonesia and Bangladesh are
among the top ten countries with the highest
prevalence of adults with diabetes—each with
Muslim populations in excess of 100 million
[36]. The population of Muslims across the
world in 2015 was estimated at 1.8 billion,
accounting for 24% of the global population;
this is projected to increase to 3 billion in 2060,
accounting for 31% of the world population
[37]. Rapid urbanization [38], calorie-dense
nutrition [39] and sedentary lifestyles con-
tribute to excess weight, which in turn increases
the risk of diabetes [40]. It is worth noting here
that much of the published data are based on
studies of T2 diabetes patient populations
exclusively or on studies of a T2 diabetes-dom-
inant study cohort with the results combining
data on T1 diabetes patients with the main
findings. Furthermore, even if T1 diabetes data
are presented, there is also the possibility of
misclassifying a patient on insulin therapy as
having T1 diabetes, especially given the
increased prevalence of obesity in Muslim pop-
ulations [41]. Such confounding factors may
also contribute to the findings being less
accurate in the context of making specific
comments on T1 diabetes and Ramadan.
The landmark Epidemiology of Diabetes and
Ramadan (EPIDIAR) study found that as many
as 42.8% of the 1080 patients with T1 diabetes
and 78.7% of the 11,173 patients with T2 dia-
betes reported fasting for at least 15 days during
Ramadan [7], leading to an estimation that
approximately 120 million people with diabetes
worldwide fast during Ramadan. Approximately
half of these patients did not change their life-
style, sleep duration, food or fluid intake and
sugar intake and the majority did not alter their
medications. The study revealed that fasting in
Ramadan was associated with significant hypo-
glycaemia. It must be noted that even though
the study excluded over 600 patients with T1
diabetes at screening as it was felt their diag-
nosis was inaccurate, of the remaining 1000?
patients, 3% were taking a sulphonylurea (SU)
to manage their condition. Thus, it is possible
that within the T1 diabetes cohort, there could
be many more who may have T2 diabetes or
another form of diabetes. Nonetheless, the
results of this study highlight the challenges
that patients and HCPs face in diabetes
Fig. 5 Changes in cortisol circadian rhythm during Ramadan showing a shift in the cortisol profile on day 7 and a return to
near baseline (non-Ramadan) values by day 21
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management during Ramadan and present the
window of opportunity for engagement prior to
and during Ramadan to make fasting a safe and
healthy experience. On the back of this study,
the American Diabetes Association (ADA) pub-
lished their first recommendation for the man-
agement of diabetes in 2005 [42]. The
publication was pioneering, and the recom-
mendations have been widely adopted across
the globe and reproduced in subsequent and
more recent national and independent guideli-
nes [43–47]. It is important that we acknowl-
edge that whilst the EPIDIAR study has been
fundamental in shaping guidance on fasting
and Ramadan, it was conducted in the early
2000s in Asian and Middle Eastern countries
where access to health services and the latest
diagnostic, monitoring treatment options for
diabetes were limited.
Another important international observa-
tional study, CREED, provided further insight
into the management and outcomes of patients
with T2 diabetes during Ramadan [6, 48].
Physicians (n = 508) across 13 countries enrol-
led patients with T1 diabetes, T2 diabetes or
gestational diabetes in the study, and data were
reported for 3250 patients with T2 diabetes.
Analysis of the data revealed that 94.2% of these
patients reported fasting for at least 15 days
during Ramadan and that 63.6% reported fast-
ing every day during the month, indicating that
many patients considered to be at high or very
high risk of adverse events still fast during
Ramadan. The findings of CREED were used to
update the 2010 iteration of the ADA recom-
mendations for diabetes in Ramadan [43]. More
recent updates from CREED have impacted on
recent guidance [47, 48].
More recently, the DAR-MENA study (2019)
showed that despite the risks associated with
fasting for people with T1 diabetes, almost one-
half of participants in the study fasted for the
full 30 days of Ramadan with no significant
change in hypoglycaemic events [49]. This
prospective study is the first to describe the
characteristics and care of participants with T2
diabetes during Ramadan in the Middle East
and North Africa (MENA) area, and the results
can be utilized in the development of evidence-
based care to ensure the safety of participants
who fast [50].
SPECIFIC RISKS AND METABOLIC
PARAMETERS IN DIABETES
IN RELATION TO RAMADAN
FASTING
Patients in preparation for Ramadan may make
changes to their treatment of their own accord
or on the advice of the HCPs. It is known that
many Muslim patients do not approach their
HCP with the concern that they may be advised
not to fast [51]. Inadequate pre-Ramadan
preparation, poor prior engagement with the
HCP, baseline suboptimal control and the stress
associated with fasting due to disturbances in
the eating patterns, sleep–wake cycles and
intercurrent illness are all factors that can
adversely affect the fasting experience.
Potential risks associated with fasting and
diabetes are disturbance in glycaemic control
manifesting as hypoglycaemia and hypergly-
caemia and metabolic emergencies, such as
diabetic ketoacidosis (DKA), hyperosmolar
hyperglycaemic syndrome (HHS), dehydration,
renal impairment and hypotension and
thrombosis secondary to hyperglycaemia and
dehydration. Further, cardiometabolic factors
such as blood pressure and lipid profiles may
also be subject to influence from Ramadan
fasting.
Glycaemic Control
In a meta-analysis carried out by Aydin et al.,
Ramadan fasting was not associated with any
significant negative effects on postprandial
(plasma) glucose or fructosamine levels. How-
ever, body mass index (BMI), glycated hae-
moglobin (HbA1c) and fasting plasma glucose
were significantly decreased [52].
A narrative literature review of all peer-re-
viewed publications looking at the health
implications of Ramadan fasting was under-
taken in 2018 [53]. The majority of studies
reviewed suggested that under normal circum-
stances, Ramadan fasting was safe for persons
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with mild and stable medical conditions. How-
ever, the authors highlighted the need for
individualized management of high-risk
patients.
Hypoglycaemia
In the EPIDAR study patient cohort, severe
hypoglycaemia requiring hospitalization
increased during Ramadan by 4.7-fold in
patients with T1 diabetes (3–14 events/100
people/month) and by 7.5-fold in those with T2
diabetes (0.4–3 events/100 people/month) [7].
With the advent of newer antihyperglycaemic
agents, such as second-generation SUs, gluca-
gon-like peptide-1 (GLP-1) analogues, insulin
analogues and sodium-glucose transporter-2
(SGLT-2) inhibitors, the rates of severe and non-
severe hypoglycaemia are fewer [54–60]. Aldawi
et al. found significant increases in the mean
amplitude of glycaemic excursions during early
Ramadan between patients on two or more
antidiabetic medicines and those on SUs [61].
Earlier research also supports the greater risk of
hypoglycaemia with SUs compared metformin
monotherapy [62]. A number of studies have
also shown the lower risk of hypoglycaemia
with newer T2 diabetes therapies compared to
SUs and their safety in Ramadan fasting
[58, 59, 63–71].
Hyperglycaemia and Ketoacidosis
The EPIDIAR study showed that during Rama-
dan the rate of hospitalization for severe
hyperglycaemia increased significantly from 1
to 5 events/100 people/month (p\0.0001) in
patients with T2 diabetes; for those with T1
diabetes, hospitalization for severe hypergly-
caemia (with or without ketoacidosis) increased
non-significantly from 5 to 16 events/100 peo-
ple/month (p = 0.1635) [7, 43]. In patients with
T1 diabetes, there was a non-significant increase
in ketoacidosis in patients with poor control
prior to Ramadan.
A number of studies examining the risk of
DKA in T1 diabetes patients have found no
increased risk [72–75]. An observational study
by Al-Agha et al. suggests that flash glucose
monitoring enabled children who wished to fast
to be able to do so without experiencing severe
hypoglycaemia or DKA [74]. A prospective study
in T1 and T2 diabetes patients showed that
active glucose monitoring, adjustment of med-
ications, dietary counselling and patient edu-
cation significantly reduced the risk of acute
diabetic complications in fasting patients [76].
In patients with T2 diabetes, the risk of
ketoacidosis is minimal during fasting, as
demonstrated by a retrospective analysis of
records of T1/T2 diabetes patients [77, 78] and
prospective observational studies undertaken in
patients with T2 diabetes [79, 80]. Earlier pub-
lications, not supported by evidence, suggested
an increased risk of DKA during Ramadan.
Beshyah and colleagues evaluated the validity
of the perceived increased risk and the actual
occurrence of DKA during fasting in Ramadan
in a non-systematic, narrative review of litera-
ture and found that the risk of DKA was not
increased during fasting [81]. Consequently,
these authors de-emphasized the earlier pro-
posed risk of DKA during Ramadan, creating a
more balanced approach for those wishing to
fast during Ramadan.
Alabbood and colleagues performed a
literature review of 16 studies that had studied
the effects of Ramadan fasting on glycaemic
control in T1 diabetes and T2 diabetes patients
[82]. Three studies in T1 diabetes/T2 diabetes
combined cohorts found significant improve-
ments in two glycaemic parameters: fruc-
tosamine and HbA1c [17, 55, 83]. Three other
studies in T1/T2 diabetes patients recorded
complications, such as severe hyperglycaemia,
severe hypoglycaemia (which required help
from others) and DKA in insulin-dependent
patients [54, 72, 76]. One study found that
short-acting analogues may be advantageous
pre-meal, as insulin lispro was found to be
associated with lower glucose excursions 2 h
post Iftaar [72]. A randomized, open-label,
crossover study also found that pre-mixed
preparations containing insulin lispro were
superior to those containing human insulins
[54]. The authors of this review suggested that
Ramadan fasting can be feasible for T1 diabetes
and T2 diabetes patients on insulin. CGM-en-
hanced insulin pump therapy and rapid-acting
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insulin like lispro or pre-mixed insulins con-
taining lispro may be advantageous when
compared to human-soluble or pre-mixed
human insulin, respectively.
Dehydration, Thrombosis
and Macrovascular Risk
Fasting in countries with hot climates and pro-
longed periods of fasting (C 18 h in countries in
the temperate regions during summer) can put
patients at risk of dehydration, which can be
exacerbated by uncontrolled hyperglycaemia
leading to osmotic diuresis. In patients with T2
diabetes, dehydration can present as low blood
pressure, lethargy, syncope, haemoconcentration
and hypercoagulability predisposing to throm-
bosis [84] and strokes [85]. Although fasting can
reduce platelet sensitivity to clopidogrel in T2
diabetes, this may be related to an increase in
glycaemia during Ramadan [86]. However, it has
been reported that the incidence of acute cardiac
illness in patients with T2 diabetes is not different
during Ramadan than at other times [87].
A prospective study was conducted into the
safety of Ramadan fasting in T2 diabetes patients
with cardiovascular heart disease (CHD) [88].
CGM was carried out using FreeStyle Libre
monitoring devices (Abbott Laboratories, Chi-
cago, IL, USA). During fasting a significant
improvement was seen in HbA1c, but a higher
incidence and prolonged duration of hypogly-
caemia was seen compared to non-fasting. Lipid
profile, BMI, renal function and systolic and
diastolic blood pressure were not significantly
altered. The authors concluded that in patients
with stable CHD who were receiving optimal
diabetes care, no adverse cardiovascular effects
were associated with Ramadan fasting.
The authors of a systematic review of the effect
of Ramadan fasting on cardiovascular events and
risk factors in patients with T2 diabetes found
insufficient evidence to link Ramadan fasting
with increased or reduced incidence of cardio-
vascular events in people with diabetes, although
there was some indication that stroke risk may be
increased [89]. Findings were noted to be incon-
sistent in terms of risk factors, as some favoured
Ramadan fasting, and others did not.
Body Weight
The effect of Ramadan fasting on anthropo-
metric parameters was studied by Khaled and
colleagues [167]. These authors reported weight
loss and a decrease in calorie intake during the
month of Ramadan. In a large cross-sectional
study, T2 diabetes patients showed an
improvement in metabolic parameters, includ-
ing BMI, during fasting in Ramadan [168].
The DAR–MENA T2 diabetes trial confirmed
statistically significant improvement in weight
and total waist circumference in people with T2
diabetes fasting during Ramadan [50], whilst
the authors of a subsequent systematic review
and meta-analysis concluded that Ramadan
fasting was associated with statistically signifi-
cant consistent—albeit transient—reductions in
weight and fat mass, especially in people who
are overweight or obese [20].
Blood Pressure Control
Samad et al. found a significant drop in both
systolic and diastolic blood pressure (SBP and
DBP, respectively) in normotensive males
before and during Ramadan fasting [90], while
Norouzy et al. found no significant difference in
the trend of 24-h blood pressure monitoring
before, during and after Ramadan in nor-
motensive and hypertensive volunteers [91]. A
significant reduction in both SBP and DBP was
shown by Salahuddin et al. in an observational
trial involving hypertensive patients on anti-
hypertensive therapy [92]. Previous findings
were discussed by Mazidi et al. in a systematic
review [93], while Hassanein et al. found
improvement in blood pressure (statistically
significant for SBP and non-statistically signifi-
cant for DBP) in a large international, multi-
centre, prospective, observational trial [50].
Lipid Profile
Metabolic parameters, including lipid profile,
have been studied in people with diabetes fast-
ing during Ramadan. Bouguerra et al. found a
negative correlation between cholesterol intake
during Ramadan and the change in high-
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density lipoprotein-cholesterol (HDL-C), which
increased by 13% at the end of Ramadan and by
23% 3 weeks after Ramadan [94].
A progressive and significant increase in
HDL-C was found by Shahab et al., in addition
to a significant decrease in total triglycerides
and low-density lipoprotein-cholesteral (LDL-C)
but not in total cholesterol [95]. Similar findings
were reported in relation to HDL-C and LDL-C
by Norouzy et al. [79]. The results of the
DAR–MENA T2 diabetes trial confirmed signifi-
cant improvements in LDL-C and total choles-
terol in people with T2 diabetes fasting in
Ramadan [50].
MANAGEMENT
General Guidance and Risk Stratification
The International Diabetes Federation (IDF) and
Diabetes and Ramadan (DAR) Practical Guide-
lines (2016) provide HCPs with relevant back-
ground information and practical
recommendations, enabling them to help peo-
ple with diabetes participate in fasting during
Ramadan, while minimising the risk of com-
plications [36]. The IDF–DAR Practical Guideli-
nes adopt a three-tiered risk stratification
matrix, with patients stratified to the very high-
or high-risk groups being advised not to fast,
and are a well-accepted stratification that can be
applied for people with diabetes prior to
Ramadan fasting. The guidance highlights the
general consensus among religious authorities
and scholars that if an individual is considered
to be at high to very high risk then they should
refrain from fasting [4]. A more detailed expo-
sition pertaining to the religious obligation of
fasting and practical considerations in relation
to health and illness with particular considera-
tion to diabetes has been published elsewhere
by authors of this review [96]. A risk-stratifica-
tion matrix adapted from IDF-DAR by the South
East London Area Prescribing Committee is
shown in Table 2 [97]. This matrix also includes
coronavirus disease 2019 (COVID-19) as a risk
factor in the context of the current pandemic.
Further below, there is linked commentary
explaining this in detail.
Diabetes patients wishing to observe the fast
are advised to attend a pre-Ramadan assessment
with their HCP at least 6–12 weeks before the
start of Ramadan (Fig. 6). Factors to be taken
into consideration during the assessment for
the purpose of risk stratification are type of
diabetes, ongoing diabetes treatment, degree of
diabetes control, individual propensity for
hypoglycaemia, competence at self-manage-
ment, previous Ramadan experience, presence
of diabetes complications and co-morbidi-
ties, ongoing or recent intercurrent illness,
degree of frailty, level of cognition, polyphar-
macy burden, occupation and social circum-
stances (Table 1).
After risk stratification, when the patient
makes an informed decision to fast, an indi-
vidualized management plan should be devel-
oped (Table 2). The decision may contradict
medical advice, but patient choice should be
respected, and patients should be supported by
HCPs on the management of their diabetes. Key
aspects to be covered during the consulta-
tion(s) in preparation for fasting are given in
Table 3.
The current DAR guidance for patients with
T1 diabetes or T2 diabetes on insulin who are
classed as having a high or very risk and
(strongly) advises these patients not to fast. The
EPIDIAR study suggests that despite this advice
from HCPs, about 40% with T1 diabetes con-
tinued to fast [5]. Findings from previous stud-
ies that have been summarized in the latest DAR
guidance suggest that only half of patients
receive any form of counselling or advice
regarding fasting [36].
With the correct advice and support from
HCPs, many people with T2 diabetes may be
able to fast safely during Ramadan. Patients
taking metformin, SUs or insulin will need to
adjust dose and/or timings to reduce the risk of
complications [97]. Guidance on dose adjust-
ments for oral and injectable therapies, includ-
ing insulin, are given in Tables 4 and 5. Newer
antiglycaemic medications, including incretin-
based therapies, are associated with a lower risk
of hypoglycaemia and may be preferable for use
during Ramadan.
Thus, to conclude a patient’s decision to fast
should be made after ample discussion with his
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or her physician or nurse, concerning the risks
involved and further discussion with a religious
authority if appropriate. Patients who insist on
fasting should undergo pre-Ramadan assess-
ment and receive appropriate education and
instructions related to physical activity, meal
planning, glucose monitoring, and dosage and
timing of medications. The management plan
must be highly individualized. Patients classi-
fied as very high or high risk, including those
with T1 diabetes and pregnant women with
diabetes, need close medical supervision if they
insist on Ramadan fasting. Further, if physicians
still have reservations about their patients fast-
ing, particularly those on insulin, particularly
when the fasts are longer in the summer in
temperate regions, one valid option from a
religious perspective is to defer the fast to the
winter when the duration is shorter and the
risks of hypoglycaemia and dehydration are
likely to be [1]. Similarly, another option is to
consider trial fasting in the month before
Fig. 6 Pre-Ramadan assessment and plan of care
Table 1 Factors to consider for risk stratification
Factors
Type of diabetes
Ongoing diabetes treatment
Degree of diabetes control
Individual propensity for hypoglycaemia
Competence at self-management
Previous Ramadan experience
Presence of diabetes complications and co-morbidities
Ongoing or recent intercurrent illness
Degree of frailty
Level of cognition
Polypharmacy burden
Occupation
Social circumstances
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Table 2 Risk stratification for patients with diabetes
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Ramadan—this can provide useful information
to the patient to the patient as well as HCP team
in arriving at a decision whether safe Ramadan
fasting is achievable.
Patient Education
The CREED study showed that patients with T2
diabetes considered to be high risk or very high
risk for fasting managed to fast successfully after
having received structured education pre-Ra-
madan [48].
The Ramadan Education and Awareness in
Diabetes (READ) study showed that pre-Ramadan
education in patients with T2 diabetes was asso-
ciated with greater weight loss and significant
reduction in hypoglycaemic events [98]. Another
study in T1 diabetes patients showed that
adjustment of drug dosage, dietary advice, patient
education and SMBG enabled patients to fast
without major complications [76].
A study from Egypt looked at the benefit of
diabetes self-management education in pro-
moting safe fasting in Ramadan in people on
insulin. This study included people attending
Ramadan reinforcement sessions as part of the
Educational Program for People with Diabetes
(EPPWD) at the Ain-Shams University Diabetes
Center in Cairo, Egypt. The number of hypo-
glycaemic events declined in these people,
which advocates the use of education for fasting
in patients with T2 diabetes [99].
The end of Ramadan is followed by the fes-
tival known as Eid ul-Fitr. This is usually marked
with festivities, sharing of food and sweet bev-
erages. Patients with diabetes should be advised
on the risks of hyperglycaemia during this time,
as many individuals overindulge in eating and
drinking. When the month of Ramadan ends,
the patient’s therapeutic regimen should be
adjusted and may be changed back to its pre-
vious regimen.
Type 1 Diabetes: Education
and Management
Most of the recent data on T1 diabetes are from
small observational studies and open-label
interventional studies during Ramadan and
consist of a mix of adult and paediatric studies.
Larger observational data from the older EPI-
DIAR study has several limitations, as men-
tioned earlier [7]. Specifically in terms of T1
diabetes, the study was conducted in MENA and
Asian countries during the mid-2000s; conse-
quently, a large proportion of people with T1
diabetes enrolled in this study were on non-
analogue, biphasic insulin rather than intensive
insulin therapy with insulin analogues. Also, a
significant proportion of the people with T1
diabetes did not have regular HCP contact or
support. What the EPIDIAR study did do was to
highlight that pre-Ramadan optimization and
education are needed and to point out the
potential risks if these are not offered. Since its
Table 2 continued
* Risk upgraded in light of COVID-19 pandemic
Adapted IDF-DAR risk stratification table, reproduced with permission from the South East London Area Prescribing
Committee [97]
CKD Chronic kidney disease, DKA diabetic ketoacidosis, DPP-4 dipeptidyl peptidase-4, GDM gestational diabetes mellitus,
GLP-1 RA glucagon-like peptide-1 receptor agonist, MDI multiple dose insulin, MTF metformin, SGLT-2 sodium-glucose
co-transporter 2, SMBG self-monitoring of blood glucose, SU sulfonylurea, T1DM Type 1 diabetes mellitus, T2DM Type 2
diabetes mellitus
a In all categories, people with diabetes should be advised to follow medical opinion due to probability of harm. The
decision to fast is a personal decision for the person with diabetes, who should be supported by the healthcare professional
(HCP) to achieve best possible outcomes
b Hypoglycaemia that is not due to accidental error in insulin dose
c The expected level of glycaemic control is to be agreed upon between HCP and patient according to a multitude of
factors. Glycated haemoglobin (HbA1c)[ 75 mmol/mol for[12 months should be used as an indicator of poor control
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publication there have been several major
advances in T1 diabetes, including structured
diabetes education programmes and new dia-
betes technologies, both of which allow safer
and improved management of T1 diabetes
[100]. Subsequent observational studies using
these advances have highlighted the potential
benefits in terms of improved glycaemic out-
comes and safer fasting with reduced hypogly-
caemia risk.
Regarding the general management of T1
diabetes, the Dose Adjustment for Normal Eat-
ing (DAFNE) programme, an educational course
for managing T1 diabetes, has been shown to
reduce severe hypoglycaemia and hypergly-
caemia and improve the quality of life of par-
ticipants [101, 102]. The importance of
education is critical in being able to apply
insulin therapy to challenging situations, such
as exercise or shift work and dose adjusting in
response to glucose data [103]. In terms of
fasting, intensive education in children
aged[11 years pre-Ramadan improved their
ability to complete fasting [75]. Regular moni-
toring and dose adjustments have been shown
to minimize hypoglycaemic events and DKA
[72]. Other educational approaches specifically
devised for Ramadan have demonstrated
Table 3 Key aspects to cover during consultation
Aspects Advice
SMBG - Importance and frequency of SMBG; identification, management and reporting of hypoglycaemia
and hyperglycaemia
Diet - Avoid foods of high glycaemic index; avoid indulgent eating
Fluids and meal
planning
- In temperate countries where fasting is prolonged or when temperatures are hot, adequate non-
sugary fluid intake is advised
Exercise - Regular light-to-moderate exercise is advised; it can be done anytime, but preferably a few hours
before Iftaar or just after a light Iftaar
- The special night prayer (Taraweeh), which can involve standing for prolonged periods, is a good
form of exercise for those who participate. This occurs within a congregation in the mosque and is
a form of exercise. Patients should keep treatment for hypoglycaemia
Smoking - Smoking invalidates a fast. Ramadan is an opportunity to promote smoking cessation
Medication review - Optimization for Ramadan fasts with particular importance given to risk of hypoglycaemia,
duration of fasts and non-diabetes medication, such as diuretic usage
When to break the
fast
- Blood glucose\ 4 mmol/L(\ 5 mmol/l if driving necessary)
- Blood glucose[ 16.7 mmol/L at any time during the fast (or pre-agreed threshold with HCP)
- Development of acute intercurrent illness causing significant physical, mental or physiological
compromise
- General deterioration in health causing significant physical, mental or physiological compromise
Driving/travel - Determine if driving is required for work and/or social activities and further stratify patients
according to risk in relation to risk of harm when fasting
- If driving whilst fasting is going to occur, give relevant advice relating to hypoglycaemia that is
compatible with both secular and religious law
Healthcre support - A HCP should be identified for advice and support
HCP Healthcare professional, SMBG Self-monitoring of blood glucose
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Table 4 A guide to dose adjustments for people taking antidiabetic agents who fast during Ramadan (Type 2 diabetes).
Table is adapted and reproduced with permission from the South East London Area Prescribing Committee [97]
Medicine Dosing Advice
Meormin 
Changes to meormin dosing 
Acarbose No dose modificaon as the risk of hypoglycaemia is low.
Thiazolidinediones 
(TZDs)
No dose modificaons. Dose can be taken in the evening (at Iaar) or in the morning (at Suhoor).
Glucagon-like 
pepde -1 receptor 
agonist (GLP-1 RAs) 
As long as GLP-1 RAs have been appropriately iniated prior to Ramadan (at least 6-8 weeks before), no 
further dose modificaons are required. If iniated less than 6 weeks before, consult iniang prescriber 
for advice.  
Sulfonylureas (SU) 
or short acng 
secretagogues e.g. 
repaglinide
Note: Higher risk of 
hypoglycaemia 
with SUs
Changes to SU and short acng insulin secretagogue dosing
Dipepdyl Pepdase -4 (DPP-4) inhibitors No dose modificaons. 
Sodium glucose co-transporter 2 inhibitors (SGLT2-i) Take in the evening (at Iaar). Ensure adequate hydraon.  
Recommended iniaon at least 4 weeks before Ramadan
Once-daily dosing 
(Both immediate and 
slow release)
No dose modificaon 
usually required
Take in the evening (at 
Iaar)
Twice-daily dosing 
(Both immediate and 
slow release)
No dose modificaon 
usually required   
Take in the evening 
(at Iaar) and 
morning (at Suhoor)
Three mes daily dosing  
Morning dose to be taken 
at Suhoor (morning)
Combine aernoon dose 
with evening dose & take 
in the evening (at Iaar)
Once-daily dosing 
Take in the evening (at Iaar)
Twice-daily dosing
Same morning and evening 
dose
Evening dose (at Iaar) 
remains unchanged. 
Consider reducing the 
morning dose (at Suhoor) in 
paents with well-controlled 
blood glucose levels by 25-
50%.
Twice-daily dosing
Higher morning and lower 
evening dose
Switch morning and evening 
dose. 
Consider also reducing the 
morning dose (at Suhoor) in 
paents with well-controlled 
blood glucose levels by 25-
50%.
Twice-daily dosing
Lower morning and higher 
evening dose
Both doses remain 
unchanged. 
Consider reducing the 
morning dose (at Suhoor) in 
paents with well-
controlled blood glucose 
levels by 25-50%.
Older drugs in the class and long-acng or modified release SU
Modified release sulfonylureas: Change to short acng preparaon e.g. gliclazide due to the risk of 
hypoglycaemia with modified release sulfonylureas and follow the advice above.
Older drugs (e.g.: glibenclamide) carry a higher risk of hypoglycaemia and should be avoided. Change to short 
acng preparaon e.g. gliclazide due to the risk of hypoglycaemia with modified release sulfonylureas and 
follow the advice above.
Second generaon Sulfonylureas (gliclazide, glimepiride) should be used in preference due to the lower risk 
of hypoglycaemia.
Three-mes daily dosing
Stop lunch me dosing. Switch morning and evening dose if the higher dose is in the morning. Consider 
reducing the morning dose (at Suhoor) in paents with well-controlled blood glucose levels by 25-50%.
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Table 5 A guide to dose adjustments for people with type 2 diabetes on insulin who fast during Ramadan
Insulin therapy Dosing advice
Basal therapy - Once-daily dosing: to be administered in the evening (at
Iftaar). Reduce dose by 15–30%
- Twice-daily dosing: lower dose to be taken in the morning
(at Suhoor). Reduce dose by 25–50%. Higher dose to be
taken in the evening (at Iftaar). No change to this dose
- Basal bolus dosing/basal plus: reduce basal dose by
15–30%. Note: bolus as per usual strategy with meals e.g.
not to be taken if the patient is not eating. Adjust bolus to
intake
Rapid- or short-acting prandial/bolus insulin - Take normal dose in the evening (at Iftaar). Omit
lunchtime dose. Reduce the morning dose (at Suhoor) by
25–50%
- Once-daily dosing: take normal dose in the evening (at
Iftaar)
Biphasic insulin, e.g. 30/70, 25/75, 50/50 (high-risk
group—winter fasting likely to be most practical and
safest option when Ramadan in summer)
- Twice-daily dosing (if equivalent doses in morning and
evening): reduce morning dose by 50% and take in the
morning (at Suhoor). Evening dose remains unchanged,
take in the evening (at Iftaar). (Consider further reduction
of morning dose if time between evening [Iftaar] and
morning [Suhoor] meals is\ 5 h)
- Twice-daily dosing (if higher dose in morning): switch the
morning and evening dose. Consider reducing the switched
dose in the morning (at Suhoor) by 50% if necessary.
(Consider further reduction of morning dose if time
between evening [Iftaar] and morning [Suhoor] meals is\
5 h)
- Twice-daily dosing (if lower dose in morning): consider
reducing morning dose by 50% if required and take in the
morning (at Suhoor). Evening dose remains unchanged.
Take at Iftaar. (Consider further reduction of morning
dose if time between evening [Iftaar] and morning
[Suhoor] meals is\ 5 h)
- Three times daily dosing: omit lunchtime dose. Adjust
morning dose and evening dose as described for twice-daily
dosing above.
Table is adapted and reproduced with permission from the South East London Area Prescribing Committee [97]
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benefits [104]. Further studies, described in
subsequent sections of this review, demonstrate
the benefits of Ramadan-specific education
comined with technology use.
With the newer analogue insulins the risks of
hypoglycaemia are reduced and improved PPG
levels can be achieved in T1 diabetes [105]. The
use of these insulins needs to be coupled with
education and frequent monitoring to achieve
any benefits in glycaemic control. Evidence
collected during Ramadan demonstrating the
advantages of analogue insulins has been
examined in several studies, mainly in the
paediatric and adolescent settings [106]. The
consensus of opinion, as reported in one of the
larger studies, is that the utility of multiple daily
injections and analogue insulin can offer
improvements in hypoglycaemia and hyper-
glycaemia [107].
The use of technology has provided patients
with T1 diabetes with further measures of safety
during Ramadan. Continuous subcutaneous
insulin infusion (CSII) via insulin pumps
enables different levels of basal insulin delivery
to be programmed and for smaller bolus doses,
thereby allowing for flexibility in settings, such
as for fasting, as well as small changes for those
are insulin sensitive. A multicentre study com-
paring CSII with multiple dose insulin (MDI)
and a recent systematic review comparing CSII
with MDI/premixed insulin regimens have
shown lower rates of severe hyperglycaemia/
hypoglycaemia and ketosis with CSII [108, 109],
better glucose variability and better adherence
to fasting [108]. Other studies have demon-
strated that patients on CSII can safely fast
during Ramadan if they have adequate pre-Ra-
madan education [110], with minimal adverse
events such as hypoglycaemia or DKA
[83, 111, 112].
More recently, the widespread use of real-
time glucose monitoring, in terms of both flash
glucose monitoring and CGM, has offered fur-
ther opportunities to reduce risks of fasting in
patients with T1 diabetes by reducing fthe
requency of hypoglycaemia and improving
metabolic control. Coupled with education,
real-time glucose monitoring can improve gly-
caemic control and hypoglycaemia frequency
during Ramadan as compared to post-Ramadan
[101, 113]. There was a mild overall improve-
ment in glycaemic outcomes during Ramadan
as compared to post-Ramadan with flash glu-
cose monitoring [74] and pre-Ramadan with
CGM [101, 113]. The linking of CGM and CSII
offers further opportunities to improve safety.
Using the low-glucose suspend function in CSII
systems further improves the safety of fasting in
adolescents and young adults [114].
Hybrid-closed loop systems offer further
potential to improve safety and improve gly-
caemic outcomes by linking CGM and CSII to
deliver insulin in an automated manner via
algorithms [115, 116]. Initial experience with a
commercially approved system demonstrates
impressive glycaemic outcomes and parallels
unpublished observations from open-source
systems [116, 117].
Recent evidence and emerging data high-
light the urgent need for updates in guidance
on T1 diabetes and fasting given the advances
in management [118]. Whilst attempts in gen-
eral dose adjustments for insulin and CSII have
been made [119], further work is needed to
detail support strategies, education, dietary
guidance and management in T1 diabetes sim-
ilar to work done in other settings [103, 118].
Pharmacological management
Metformin
Metformin works by improving insulin sensi-
tivity [120]. Therefore, the hypoglycaemia risk
induced by metformin is very low. Although
there are no studies that have observed the
incidence of hypoglycaemia in those patients
on metformin monotherapy and fasting, met-
formin is deemed safe to take during the month
of Ramadan due to its low risk for hypogly-
caemia [36].
The daily dose of metformin does not need
to be altered, but some adjustments to the
dosage interval are required for those on three
times daily dosing. Such patients should take
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their lunchtime dose at Iftaar. Those on a pro-
longed-release formulation, which is usually
taken once daily, should take their usual dose at
Iftaar [45].
Acarbose
Acarbose inhibits the actions of alpha-glucosi-
dase enzymes in the brush border of small
intestines and pancreatic alpha-amylase, thus
slowing down the absorption of glucose and
modifying insulin secretion [121]. Like met-
formin, no dose adjustment of acarbose is nee-
ded during Ramadan as the risk of
hypoglycaemia is low [36]. The combination of
fasting-associated alteration in gut motility
[122] and gut microbiota [123] can in theory,
predispose a fasting individuals to the known
gastrointestinal side-effects of acarbose. For
patients who are prescribed acarbose three times
daily, frequency can be reduced to twice daily
coinciding with Suhoor and Iftaar. The dose
taken with Suhoor can be reduced or even
stopped during Ramadan, in view of the ensu-
ing prolonged period of fasting.
Thiazolidinediones
Thiazolidinediones, such as pioglitazone, lower
glucose by improving glucose uptake in
peripheral tissues and by reducing insulin
resistance [124]. Because of the low hypogly-
caemia risk, thiazolidinediones are valuable
agents to use during Ramadan [44]. It is worth
noting that this class of drug should be initiated
10–12 weeks before Ramadan because of its slow
maximal antihyperglycaemic effect [43].
To date, only study has researched the use of
thiazolidinediones during Ramadan. This dou-
ble-blind randomized controlled trial on
pioglitazone found that when compared to
placebo, the addition of pioglitazone to the
patient’s usual hypoglycaemic regimen did not
increase the risk of hypoglycaemia. Pioglitazone
also significantly improved glycaemic control
during the early, mid- and post-Ramadan peri-
ods [125].
No dose adjustment of thiazolidinediones is
required during Ramadan, and doses can be
taken with Iftaar or Suhoor.
Insulin Secretagogues
Meglitinide Short-acting insulin secretagogues
(IS), such as the meglitinides repaglinide and
nateglinide, work by increasing insulin secre-
tion through their stimulation of the pancreatic
b cells [126]. Studies examining the safety and
efficacy of meglitinides and SUs for patients
fasting during Ramadan are summarized in
Table 6.
An observational study carried out in Turkey
showed that there was no difference in the risk
of hypoglycaemia when repaglinide, was com-
pared to glimepiride and insulin glargine [55].
Another observational study demonstrated that
there were no hypoglycaemic events when
repaglinide was combined with insulin glargine
[56], and similar results were seen by Anwar
et al. [127], who compared repaglinide with
glimepiride and found no difference in the
incidence of hypoglycaemia between the two
drugs.
Therefore, the short-acting duration of the
meglitinides nateglinide and repaglinide make
them favourable for use during Ramadan as
they carry a low hypoglycaemia risk. As these
agents are usually taken three times daily with
main meals, their dosing will need to be adjus-
ted during Ramadan to twice daily dosing so
that they can be administered at Iftaar and
Suhoor.
Sulphonylureas
Similar to the meglitinide class of oral antidia-
betic agents, SUs stimulate insulin secretion
from pancreatic b cells [128]. However, their
mechanism is glucose independent, resulting in
a higher risk of hypoglycaemia and therefore
making their use during Ramadan a concern.
The timing of taking SUs during Ramadan is
key to their safety and efficacy. Although we
advise changing patients on modified-release
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(MR) preparations to standard-release ones
(Table 4), in those patients for whom this can-
not be done for reasons such as patient prefer-
ence or practicality of administration, switching
the morning MR dose to the evening can be
done safely without causing excessive hypogly-
caemia [129]. A recently published real-world
multinational observational study has shown
that MR gliclazide between 60 and 90 mg dose
taken daily at Iftaar is associated with a low risk
of hypoglycaemia and weight gain whilst
maintaining control, in fasting patients with
HbA1c\9% [130]. Similarly, glimepiride was
associated with fewer hypoglycaemic events
when the morning dose was switched to the
evening at Iftaar [131].
The duration of action of SUs taken during
Ramadan should be considered. The use of
glibenclamide has been shown to result in more
hypoglycaemic events when compared to gli-
mepiride, gliclazide [132] or repaglinide [133].
The use of older and longer-acting agents, such
as glibenclamide, should be avoided during
Ramadan and the patient switched to a short-
acting SU or to repaglinide [55].
The newer generation of SUs, such as glip-
izide, glimepiride and gliclazide, are associatged
with a lower risk of hypoglycaemia and are
therefore safer to take during Ramadan [134].
We recommend that patients on gliclazide
should halve the morning dose and take the
usual dose in the evening as Iftaar tends to be
the larger meal and characterized by a higher
glycaemic index. Doses of gliclazide should be
switched around if patients are taking a larger
dose in the morning and a smaller dose in the
evening. Glipizide that is taken once daily
should be taken at Iftaar during Ramadan to
minimize hypoglycaemia risk.
For those on combination therapy with long-
acting insulin, insulin and SU dose should be
carefully titrated to minimize the risk of hypo-
glycaemia [135].
Insulin
Several studies have provided evidence for the
use of insulin in patients with T2 diabetes who
fast during Ramadan (Table 7). Rapid-acting
insulin analogues, such as insulin lispro, have
been shown to induce lower rates of hypogly-
caemia than human insulin [136]. Long-acting
insulins, such as insulin glargine, have been
found to be safe as monotherapy [55] or in
combination with an IS such as repaglinide [56].
However, for those on combination therapy
consisting of insulin and an IS, dose titration is
required to minimize the risk of hypoglycaemia
[135].
Studies have also focussed on ensuring the
safety and efficacy of pre-mixed insulins. In an
observational study, premix insulin 30/70
(glargine or regular insulin) was found to be just
as safe, in terms of hypoglycaemia, DKA or HHS,
as long-acting insulin, provided the doses of
insulin are reduced by 75% during pre-Ramadan
assessment [80].
Soewondo et al. reported that use of biphasic
insulin aspart was safe whilst fasting as there
was a significant improvement in all glycaemic
indices measured and a reduction in hypogly-
caemic events compared to baseline, and no
associated weight gain [137]. Other studies
comparing premixed analogue insulins with
human insulins have shown that premixed
analogue insulins provide better average daily
glucose control, especially around Iftaar time,
without any increase in hypoglycaemia
[54, 138]. The combinations of long-acting and
premixed insulins can be used to the advantage
of the fasting individual by using pre-mixed
insulin with the larger meal in the day, which is
usually the Iftaar, and long-acting insulin with
the smaller meal, which is generally Suhoor
[139]. This approach can be tailored to the
individual as this pattern of eating may vary
among individuals.
Second-generation insulins may offer less
glycaemic variability and hypoglycaemia and
hence have a potential for use in Ramadan. The
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combination of insulin degludec/degludec and
aspart insulin (IDegAsp) has been shown to be a
safe and efficacious therapy during Ramadan
[64, 140]. In a recent real-world observational
study, patients with T2 diabetes fasting in
Ramadan who were taking insulin glargine 300
units/ml showed a low risk of severe/symp-
tomatic hypoglycaemia and improved control
[141].
The use of insulins, ranging from rapid-act-
ing to long-acting analogues, ultra-long acting
insulins and, pre-mix insulins, has been found
to be safe and efficacious in Ramadan. Doses
and timing should be adjusted in the pre-Ra-
madan assessment, and patients should be
supported during Ramadan with dose titration
in order to optimize their glycaemic control and
thus their fasting experience.
Dipeptidyl Peptidase-4 Inhibitors
Dipeptidyl peptidase-4 inhibitor (DPP4i) drugs
are oral hypoglycaemic agents that block the
breakdown of endogenous GLP-1, which leads
to the glucose-dependent release of insulin.
They thus carry a low risk of hypoglycaemia,
even when the patient is in the fasting state.
Patients on DPP4i are considered to be a low risk
for fasting, without a need for dose titration,
and a number of trials have been conducted on
the safety of this class of antihyperglycaemic
agents administered with or without SU during
Ramadan. Gray et al. performed a systematic
review and meta-analysis of 16 studies con-
ducted during Ramadan, ten of which com-
pared DPP4i with a SU [65]. In this meta-
analysis, one RCT did not show statistical dif-
ference in weight and HbA1c, and a second
study did not show statistical difference in
HbA1c. In two observational studies, sitagliptin
significantly decreased the number of patients
with C 1 hypoglycaemic events in Ramadan
[66], and vildagliptin led to significant decreases
in HbA1c and weight versus a SU [67]. DPP4i led
to fewer hypoglycaemic events compared to a
SU.
Overall, studies conducted to date on the use
of DPP4i in fasting T2D patients in Ramadan
(Table 8) demonstrate a better tolerability and
adherence, low rates of hypoglycaemia, better
glycaemic control and potential less weight gain
compared to a SU. Patients on DPP4i do not
require treatment modifications during Ramadan.
Glucagon-Like Peptide-1 Receptor Agonists
Glucagon-like peptide-1 receptor ago-
nists (GLP1 RA)s are drugs that mimic the
function of endogenous incretin hormones and
reduce blood glucose by glucose-dependent
insulin release. They can also lead to reduced
glucagon secretion and increased glucose
uptake and can also delay gastric emptying and
stimulate satiety centre by central effects [142].
GLP1 RAs are considered to represent as low risk
for hypoglycaemia as monotherapy although in
combination with SUs or insulin they may have
the potential for hypoglycaemia [143].
Studies examining the safety and efficacy of
GLP1 RAs for patients fasting during Ramadan
are summarized in Table 9.
A large multinational open-labelled RCT
(Lira-Ramadan) examined the effect of liraglu-
tide (n = 171) compared to SU (n = 172) in T2
diabetes patients fasting in Ramadan and
showed that no patient in either group experi-
enced severe hypoglycaemia. Those in the
liraglutide group had no major hypoglycaemic
events and achieved a target HBA1c of\7.0%,
which was significantly better than those in the
SU group (53.9 vs. 23.5%; p\ 0.001) [68].
An RCT in the UK that compared liraglutide
as monotherapy or in combination with met-
formin (n = 47) with SU (n = 52), showed no
severe hypoglycaemia in both groups and sig-
nificantly lower self-reported episodes of hypo-
glycaemia (B 3.9 mmol/L) in the liraglutide
group. Further analysis 12 weeks after Ramadan
showed a significant reduction in HbA1c, weight
and diastolic blood pressure in those patients
on liraglutide [69].
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The authors of an observational study exam-
ining the safety and efficacy of liraglutide [59] and
those of an open-label parallel-group clinical trial
comparing lixisenatide with SU [70] concluded
that both drugs were safe and led to a reduced
frequency of hypoglycaemia in Ramadan.
Given the safety and efficacy of GLP-1 ana-
logues demonstrated by these studies (Table 9),
during Ramadan fasting, we recommend that
members of this class of medications be con-
sidered as options for second-line agents to
optimize diabetes control.
Sodium-Glucose Cotransporter-2 Inhibitors
Sodium-glucose cotransporter-2 inhibitors
(SGLT-2i)s work by reducing the reabsorption of
glucose through the proximal convoluted
tubules of the kidneys by inhibiting the SGLT-2
receptors [144], a mechanism which can in turn
lead to caloric loss with a reduction in HbA1c as
well as weight loss. There is, however, a poten-
tial for an increased risk of dehydration with the
use of these medications, although recent
studies have shown that this risk is not high in
temperate climates [145].
Due to potential concerns regarding volume
loss, dehydration and postural hypotension,
Muslim doctors in the Middle East were sur-
veyed; all of those surveyed had substantial
experience with patients who fast for Ramadan.
Analysis of the results revealed that most
respondants felt safe prescribing SGLT-2is dur-
ing Ramadan [146].
Studies examining the safety and efficacy of
these medications for patients fasting during
Ramadan are summarized in Table 10. The first
study to be carried out, by Wan Seman et al.
[71], compared the use of the SGLT-2i dapagli-
flozin with SU in 110 patients in Malaysia with
T2 diabetes. This was an open-label study that
showed a significantly reduced frequency of
hypoglycaemia in the SGLT-2i arm versus the
SU arm. In terms of adverse events there was
non-significant increased risk of urinary tract
infection and postural hypotension in patients
in the the SGLT-2i arm compared to patients in
the sulphonylurea arm. There was no report of
DKA [71].
Another non-randomized parallel-cohort,
prospective observational study enrolled
patients taking canagliflozin (n = 162) or any
SU(n = 159) added to metformin ± DPP4i [60].
There was a near-significant (p = 0.09) reduc-
tion in the frequency of hypoglycaemia in the
SGLT-2i arm versus the SU arm. However, there
was a non-significant increased reporting of at
least one volume depletion event in the SGLT-2i
arm (9 vs. 3.8%).
Finally, a small single-centre prospective
observational controlled cohort study in Singa-
pore examining the effect of effect of SGLT-2i
use on ketonaemia, blood pressure and renal
function in T2 diabetes patients (n = 68) during
Ramadan showed neither an increase in keton-
aemia nor an increase in deterioration of esti-
mated glomerular filtration rate (eGFR) and
hypoglycaemia. Both groups had a similar
change in weight, eGFR, sitting systolic, sitting
diastolic blood pressure and plasma b-OHB
level. The proportion of patients experiencing
at least one hypoglycaemic event during fasting
non-significantly increased in the control group
and decreased in the study group [63].
Despite some concerns, studies have actually
demonstrated that SGLT-2i remain a safe class
of drugs during the fasting month of Ramadan.
However, we would advise the usual caveats of
patients being aware of sick day rules and
ensuring that they are properly hydrated to
minimize the risks of these drugs.
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Table 6 Summary of evidence on the safety and efficacy of meglitinides and sulfonylureas during Ramadan
First author
of study/
publication
year
Intervention Characteristics Outcomes
Cesur/2007
[55]
Comparison of glargine, repaglinide
and glimepiride on HbA1c, FBG,
postprandial blood glucose,
fructosamine and lipid levels and
risk of hypoglycaemia.
Observational, single site,
Turkey.
N = 49; fasting
N = 16; control (non-
fasting)
- No differences in HbA1c and
fructosamine amongst the three
drug groups, but prandial blood
glucose was higher in the control
group post-Ramadan and 1-month
post-Ramadan (p\ 0.05 and
p\ 0.001, respectively).
- High fructosamine levels in both
control and fasting group.
- Risk of hypoglycaemia did not differ
between the drug groups
- No changes in lipid profile noted in
fasting diabetics
Salti/2009
[135]
Comparison of incidence of
hypoglycaemia when glargine is
combined with glimepiride
Open, descriptive,
multicentre, prospective
study
N = 349: insulin-naı¨ve
(n = 100) or previously
insulin-treated (n = 249)
- Only one episode of severe
hypoglycaemia occurred in each
time period before, during and after
Ramadan.
Mild hypoglycaemic episodes
increased from 156 pre-Ramadan to
346 during Ramadan (p\ 0.001)
and decreased to 153 post-Ramadan
(p = 0.0002)
- FBG and HbA1c improved during
the titration period and did not
change during the rest of the study
Bakiner/
2009 [56]
Comparison of incidence of
hypoglycaemia when glargine is
combined with repaglinide
N = 7; fasting
N = 7; control (non-
fasting)
- No hypoglycaemic events recorded
in both groups
- No changes in HbA1c and
fructosamine were observed in both
groups
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Table 6 continued
First author
of study/
publication
year
Intervention Characteristics Outcomes
Zargar/
2010
[129]
Evaluating the effect on incidence of
hypoglycaemia when modified-
release gliclazide 60 mg is switched
from morning administration to
evening during Ramadan
Observational, multi-
country study involving
Bangladesh, India and
Pakistan
N = 136; all males
- FBG decreased by 0.01 mmol/L
(95% CI 0–0.2; p = 0.3) with
evening medication by the end of
Ramadan and increased by
0.2 mmol/L (95% CI 0.1–0.3;
p = 0.01)] after reverting to
morning medication
- There were 5 (3.7%) hypoglycaemic
episodes before, 3 (2.2%) during and
2 (1.5%) after Ramadan
Aravind/
2011
[132]
Comparison of glibenclamide,
gliclazide, and glimepiride ± MTF
on incidence of hypoglycaemia
Observational, multisite
study
N = 1378
- 19.7% of the participants
experienced C 1 symptomatic
hypoglycaemic event during
Ramadan, with incidences of 25.6,
16.8 and 14.0% observed in subjects
treated with glibenclamide,
glimepiride and gliclazide,
respectively
- The overall incidence of severe
hypoglycaemic events was 6.7%,
with the highest incidence occurring
in the glibenclamide group
Mafauzy/
2002
[133]
Comparison of repaglinide and
glibenclamide on HbA1c,
fructosamine levels and incidence of
hypoglycaemia.
Observational study
N = 255
- The number of hypoglycaemia
events was significantly lower in the
repaglinide group (2.8%) than in
the glibenclamide group (7.9%)
(p = 0.001).
- Fructosamine levels were
significantly reduced in the
repaglinide group (p\ 0.05), but
this was not seen with glibenclamide
group
- There was no significant difference
in HbA1c between the two groups
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First author
of study/
publication
year
Intervention Characteristics Outcomes
GLIRA
study
group/
2005
[131]
Evaluating the effect on incidence of
hypoglycaemia when glimepiride is
switched from morning
administration to evening during
Ramadan
Open-label, prospective,
observational study
carried out in 33 centres
in 6 countries
N = 323; glimepiride
- The incidence of hypoglycaemia
during Ramadan was similar to that
in pre- and post-Ramadan: 3% in
newly diagnosed patients and 3.7%
in previously treated patients
Anwar/2005
[127]
Comparison of repaglinide and
glimepiride on HbA1c and
incidence of hypoglycaemia
Observational study
N = 41; SU ± MTF and
repaglinide (n = 20) or
SU ± SU and
glimepiride (n = 21)
- Those participants on triple doses
of repaglinide were redistributed to
two pre-prandial doses
- Blood glucose was significantly
lower in the glimepiride group than
in the repaglinide group both during
and after Ramadan
- There was no statistically significant
difference in the incidence of
hypoglycaemia between the two
groups during and after Ramadan
CI Confidence interval, FBG fasting blood glucose
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Table 7 Summary of evidence for the use of insulins during Ramadan
First author
of study/
publication
year
Intervention Characteristics Outcomes
Akram/1999
[136]
Comparison of insulin lispro
with soluble human insulin
Open-label, randomized
cross-over study
N = 70
Hypoglycaemic events:
- Inulin lispro 1.3 ± 0.1 vs. soluble
insulin 2.6 ± 0.2 (p\ 0.002)
Mattoo/2003
[54]
Comparison of insulin lispro
mix 25 with human insulin
30/70
Open-label, multicentre,
randomized, cross-over
study
N = 151
- Average daily blood glucose: insulin
lispro mix 25 9.5 ± 2.4 vs. human
insulin 30/70 10.1 ± 2.5 (p = 0.004)
- 2-h PPG: insulin lispro mix 25
3.4 ± 2.9 mmol/l vs. human insulin
30/70 4.0 ± 3.2 (p = 0.001)
- Pre-meal FBG lispro mix 25
7.1 ± 2.2 mmol/l vs. human insulin
30/70 7.5 ± 2.6 mmol/l (p = 0.034)
Cesur/2007
[55]
Comparison of glimepiride,
repaglinide and glargine
Non-fasting control group
Observational study
N = 65
- No significant change from pre-
Ramadan FBG, PPG and HbA1c
- No significant difference in
hypoglycaemic events between fasting
and non-fasting groups
Bakiner/2009
[56]
Repaglinide ? glargine Observational study
N = 14
- Glucose control remained unchanged
between groups
- No hypoglycaemic events noted
Salti/2009
[135]
Effects of use of glargine and
glimepiride during Ramadan
fasting
Open, descriptive,
multicentre, prospective
study
N = 359
- Mild hypoglycaemic episodes increased
from 156 pre-Ramadan to 346 during
Ramadan (p\ 0.001) and decreased to
153 post-Ramadan (p = 0.0002).
Hassanein/
2018 [64]
Comparison of IDeg/Aspart
versus biphasic insulin aspart
30
Phase 3, multicenter,
international, open-label,
randomized, treat-to-
target trial
N = 263
- IDegAsp group significantly lower
overall/nocturnal hypoglycaemia rates
with similar glycaemic efficacy compared
to BIAsp30
- IDegAsp did show a significantly lower
pre-Iftaar SMBG
Kalra/2016
[140]
Patients switched from
premixed and NPH to
IDegAsp or IDeg
Real-world observational
study
N = 6
- No severe hypoglycemia
- 3 patients had 11 episodes of
symptomatic hypoglycaemia
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First author
of study/
publication
year
Intervention Characteristics Outcomes
Soewondo/
2009 [137]
Biphasic insulin aspart as
monotherapy or in
combination with oral
hypoglycaemic agent
Multicentre prospective
non-interventional study
N = 152
- Hypoglycaemic event reduced compared
to baseline
- Fasting plasma glucose, 2-h PPG and
HbA1c all improved significantly
- No increase in weight
Hui/2010
[138]
Comparison of Humalog mix
50 with human insulin mix
30
Observational study
Group 1: Humalog mix 50
and human insulin mix
30
Group 2: Human insulin
mix 30 twice daily
N = 52
HbA1c D:
- Group 1 reduction by 0.48%
(p = 0.0001) before and after Ramadan.
- Group 2 increased by 0.28% (p = 0.007)
during Ramadan
- Mean number of hypoglycaemic events
during Ramadan
- Group 1 reduction of 0.04 (p = 0.81)
- Group 2 increase of 0.15 (p = 0.43)
- These differences between the groups
were not statistically significant following
adjustment for baseline factors (least
squares mean difference between
groups = 0.135, p = 0.36, 95% CI
- 0.16 to 0.43)
Shehadeh/
2015 [139]
Insulin detemir at Suhoor and
premixed insulin at Iftaar.
Control group was standard
care
Open-label, controlled,
randomized, non-
inferiority study
N = 238
- Intervention arm was non-inferior to
standard care arm
- Mean 4P-SMBG during days 23–30 of
treatment (155 [SD 30.76] mg % and
159 [SD 33.24] mg %, respectively,
p = 0.269]
- Hypoglycaemia event rate was lower in
the intervention group (0.00 [SD 0.01]
vs. 0.01 [SD 0.03], p B 0.001)
BIAsp30 Biphasic insulin aspart 30/70, IDeg Insulin degludec, IDeg/Aspart co-formulation insulin degludec/insulin aspart,
NPH neutral protamine hagedorn (insulin), PPG postrandial glucose, SD standard deviation, 4P 4-point D change
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Table 8 Summary of evidence for the use of dipeptidyl peptidase-4 inhibitors during Ramadan
First author
of study/
publication
year
Intervention Characteristics Outcomes
Devendra/
2009 [161]
Comparison of hypoglycaemic events,
HbA1c, bodyweight changes with
vildagliptin and gliclazide as add-on to
MTF
Observational
prospective cohort
study
N = 52
Hypoglycaemia incidence
(BG\ 3.5 mmol/L):
- Vildagliptin 7.7%; gliclazide 61.5%
(p\ 0.001)
Body weight D:
- Vildagliptin: ? 0.34 kg; SU:
? 0.8 kg (p\ 0.001)
HbA1c D:
- Vildagliptin - 1.26%; SU
- 1.23% (p = 0.8217)
Hassanein/
2011 [67]
Comparison of incidence of
hypoglycaemia events between
vildagliptin and SU; MTF in both arms
Double-blinded RCT
N = 59
- No hypoglycaemia with
vildagliptin
- 34 hypoglycaemic events (15
patients, 41.7%) including 1 severe
with SU
- Mean HBA1c difference between
groups: - 0.5% (p = 0.0262)
Sifri/2011
[162]
Comparison of incidence of symptomatic
hypoglycaemia between sitagliptin and
SU
Prospective RCT
N = 1021
Hypoglycaemia incidence:
- 6.7% with sitagliptin vs. 13.2%
with SU (p\ 0.001)
Aravind/2012
[66]
Comparison of incidence of symptomatic
hypoglycaemia between sitagliptin and
SU
Prospective RCT
N = 848
Hypoglycaemia incidence:
- 3.8% with sitagliptin vs. 7/3% with
SU
Halimi/2013
[163]
Real-world study assessing rate of
hypoglycaemia with vildagliptin-treated
patients vs. IS
Prospective, non-
interventional study
N = 218
Percentage patients with severe
hypoglycaemia and/or an
unscheduled medical visit due to
hypoglycaemia:
- IS vs. vildagliptin (10.4 vs. 2.6%,
respectively; p = 0.029).
Percentage patients who had
missed C 5 doses lower in the
vildagliptin (8.5%) vs. IS (15.4%)
group
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First author
of study/
publication
year
Intervention Characteristics Outcomes
Shete/2013
[164]
Comparison of effects of vildagliptin and
SU with or without MTF
Non-interventional,
open-label,
observational study
N = 97
Hypoglycaemia incidence:
- Vildagliptin 0; SU 4.8%
- HbA1c D:
- Vildagliptin - 0.43%: SU ? 0.01%
(p = 0.009)
Body weight D:
- Vildagliptin - 1.2 kg; SU 0.03 kg
(p\ 0.001)
Al-Arouj/
2013 [165]
Real-world study assessing the effect of
vildagliptin compared to SU
Non-interventional
observational study
N = 1315
Hypoglycaemic events:
- Vildagliptin vs. SU: 5.4 vs. 19.8%,
respectively (p\ 0.001)
HbA1c D:
- Vildagliptin – 0.24%, SU ? 0.02%
(p\ 0.001)
Body weight D:
- Vildagliptin – 0.76 kg, SU
- 0.13 kg (p\ 0.001)
Malha/2014
[166]
Comparison of hypoglycaemic events,
HbA1c, bodyweight changes in patients
on vildagliptin ? MTF and
gliclazide ? MTF
Randomized, open-
label, trial
N = 69
Hypoglycaemia incidence:
- Vildagliptin 19%; gliclazide 26%
(p = 0.334)
HbA1c D:
- Vildagliptin - 0.83%; gliclazide
0.96%
BMI D:
- Vildagliptin - 0.7 kg/m2; SU
? 0.9 kg/m2
Hassanein/
2014 [58]
Comparison of incidence of
hypoglycaemia events between
vildagliptin and SU
Prospective cohort
double-blinded
randomized
observational study
N = 557
Hypoglycaemia (\ 3.9 mmol/
L ± severe):
- Vildagliptin 3.0% vs Gliclazide
7.0%, p = 0.039
IS Insulin secretagogues, RCT randomized controlled trial
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Table 9 Summary of evidence for the use of glucagon-like peptide-1 receptor agonists during Ramadan
First author of
study/publication
year
Intervention Characteristics Outcomes
Azar/2015 [68] Comparison of liraglutide 1.8 mg and
SU; MTF in both arms
Open-label, randomized,
active-controlled, parallel-
group trial
N = 341
HbA1c D:
- Liraglutide (- 0.59%) vs. SU
(- 0.38%), p\ 0.0001
Weight D:
- Liraglutide[ SU (by
- 0.54 kg), p = 0.0091
Hypoglycaemia:
- Liraglutide (2%) vs. SU (11%),
fewer with liraglutide
Brady/2014 [69] Comparison of SU with the
liraglutide; MTF in both arms
Open-label, randomized, trial
N = 99
Self-recorded blood
glucose B 3.9 mmol/L:
- Liraglutide (25%) vs.
SU (46.2%), p\ 0.0001
Weight change up to 3rd week of
Ramadan:
- Liraglutide (- 0.42 kg) vs. SU
(- 2.23 kg), p = 0.02
Change in diastolic blood
pressure 12 weeks post-
Ramadan:
- Liraglutide (- 6.18 mmHg) vs.
SU (- 0.65 mmHg), p = 0.03
Khalifa/2015 [59] To assess the safety and efficacy of
liraglutide during Ramadan
Observational study
N = 111
- Hypoglycaemia reported in 18
patients (16.2%)
- HbA1c D from 8.0 to 7.4%
(p = 0.000)
Hassanein/2018
[70]
To examine the hypoglycaemic
potential of lixisenatide as an add-
on to BI
Phase 4, randomized, open-
label, parallel-group clinical
trial
N = 184
Hypoglycaemia:
- Lixisenatide ? BI ( 4.3%;
4/92) vs. SU ? BI (17.4%;
16/92)
HbA1c D was similar-
- LS ± SE - 0.4 ± 0.1% for
lixisenatide ? BI
- LS ± SE - 0.5 ± 0.1% for SU
? BI
BI Basal insulin, LE least squares, SE standard error
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Chronic Kidney Disease
Muslims with diabetes have a high risk of
developing chronic kidney disease (CKD). Fast-
ing during Ramadan has been reviewed else-
where for this patient population, but there is a
concern about deterioration in renal disease in
susceptible patients due to dehydration [147].
Frequent and prolonged hypoglycaemia has
been reported in T2 diabetes patients with CKD
stage 3 who fast during Ramadan based on
FreeStyle Libre flash continuous glucose
Table 10 Summary of evidence for sodium-glucose cotransporter-2 inhibitors during Ramadan
First author
of study/
publication
year
Intervention Characteristics Outcomes
Wan Seman/
2016 [71]
Comparison of dDapagliflozin to
SU; MTF in both arms
Open-label RCT, Malaysia
N = 110
HbA1c D:
- Dapagliflozin (0.05%) vs. SU (0.32%)
Hypoglycaemia:
- Dapagliflozin (6.9%) vs. SU (28.8%),
p = 0.002
Hassanein/
2017 [60]
Comparison of canagliflozin to
SU; MTF ± DPP4i in both
arms
Non-randomized, parallel-
cohort, prospective,
comparative,
observational study
N = 321
HbA1c D:
- Canagliflozin (0.04%) vs. SU (0.20%)
Hypoglycaemia:
- Canagliflozin (3.7%) vs. SU (13.2%),
p = 0.009
Volume depletion:
- Canagliflozin (9.3%) vs. SU (3.8%)
Shao/2018
[63]
Study of the effect of SGLT-2
inhibitor use on ketonaemia,
blood pressure and renal
function
Single-centre prospective
observational controlled
cohort study
N = 68
Continued use of SGLT2 inhibitors
during Ramadan did not increase
ketonemia, nor increase risk of eGFR
deterioration and hypoglycaemia
Mean change in:
- Weight: - 1.8 vs. - 1.1 kg
(p = 0.205)
- eGFR: - 6.0 vs. - 4.2 mL/min/
1.73 m2 (p = 0.399)
- Systolic BP: - 8.1 vs. - 10.4 mmHg
(p = 0.569)
- Diastolic BP: - 3.7 vs. - 3.5 mmHg
(p = 0.934)
- Plasma b-hydroxybutyrate: - 0.01 vs.
- 0.02 mmol/L (p = 0.649)
BP Blood pressure, eGFR estimated glomerular filtration rate
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monitoring (FSL-CGM) [148]. However, there is
little robust evidence available to guide clini-
cians, i.e. in the form of RCTs or large-scale
observational studies in patients with CKD;
consequently, advice may have to be guided by
the duration of fasting. In equatorial countries,
the duration of fasting varies little from year to
year and is stable at around 12–14 h, whereas in
temperate countries, the duration of fasting
may vary from 8 h in the winter to 20 h in the
summer. In the absence of adequate evidence,
HCPs may have to give advice based on best
available guidance. The IDF-DAR Ramadan and
Diabetes guidelines classifies people with CKD
as ‘‘High’’ or ‘‘Very High’’ risk, and hence it
seems reasonable for a clinician to suggest to a
person with CKD stages 3–5 that they should
avoid fasting. Patients who wish to fast despite
advice to the contrary, however, should be
supported to do so safely. Advice to such
patients will include encouragement to drink
plenty of fluids during the non-fasting period—
perhaps a measured amount each day, depend-
ing on fluid status—and to check electrolytes
and creatinine in the middle of the fasting
month to aid those with advanced CKD in
deciding whether they should continue fasting.
Whilst a number of studies of people on dialysis
suggest that some people are able to fast, fasting
amongst patients on dialysis should not be
encouraged. People with stable renal trans-
plants on stable immunosuppression, however,
are probably able to fast safely providing they
are monitored carefully by their transplant team
before, during and after Ramadan.
Pregnancy
Although exempt, many pregnant Muslim
women insist on fasting during the month of
Ramadan. A large meta-analysis of 22 studies
involving 31,373 pregnancies looked at out-
comes of pregnancy during Ramadan [149].
Primary outcomes for this study were perinatal
mortality, preterm birth (before 37 weeks of
pregnancy) and small for gestational age (SGA)
infants (as defined by each study or below the
tenth centile for gestational age). Secondary
outcomes included stillbirth, neonatal death,
maternal death (the death of the mother during
pregnancy or the first 6 weeks postnatally),
hypertensive disorders of pregnancy, gesta-
tional diabetes, congenital abnormalities, seri-
ous neonatal morbidity, birth weight
(continuous variable), low birth weight
(\2500 g), very low birth weight (\1500 g),
extremely preterm birth (\ 28 weeks gestation)
and placental weight. Of the co-primary out-
comes, only for preterm birth was there suffi-
cient data, showing no significant effect of
fasting. Data were available for some secondary
outcomes, including birth weight, placental
weight and low birth weight; only placental
weight was significantly reduced by Ramadan
[149]. However, this result was dominated by
one study [150]. A small study looked at gly-
caemic control among pregnant women with
diabetes on insulin who fasted during Ramadan
and concluded that women were able to fast
safely without any adverse effects on their dia-
betes control [151].
We therefore conclude that fasting during
Ramadan while pregnant is an important per-
sonal decision and that all potential risks to
mother and foetus should be explained to the
mother. A more cautious stance is warranted,
particularly when co-morbidities are present.
Those who insist on fasting should be managed
by an expert team and receive focussed educa-
tion relating to self-management skills, such as
modifications to diet and insulin regimens and
frequent blood glucose monitoring to ensure
good pregnancy outcomes. Guidance on termi-
nating the fast and abstaining from subsequent
fasts should also be clearly communicated, with
emphasis that in the appropriate circumstances
this is a responsible, entirely valid and indeed
recommended action from a Shari’ah perspec-
tive [96].
Other Forms of Diabetes Mellitus
There is presently no evidence on the manage-
ment of diabetes during Ramadan fasting for
specific types of diabetes, such as monogenic
diabetes syndromes, neonatal diabetes mellitus
(NDM) and MODY, diabetes secondary to pan-
creatic disease (cystic fibrosis or pancreatitis),
medications such as glucocorticoids, human
immunodeficiency virus treatment or post-
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transplantation diabetes mellitus, to allow for
the creation of specific guidance.
Treatment is based on first principles and is
determined by the clinical presentation and
laboratory parameters. For example, pancreatic
exocrine insufficiency may present in up to
1.8% of patients newly diagnosed with diabetes;
this tends to be a more brittle form of diabetes,
requiring early insulin therapy [152]. Given the
rapid fluctuation in glucose control, many
patients with this condition may require MDI
and should be treated in Ramadan as one would
treat a person with T1 diabetes. MODY affects
2% of all patients with diabetes aged B 20 years
[153]. With the exception of glucokinase-
MODY (MODY 2), which is the mildest form of
MODY, all other forms mimic T1 diabetes or T2
diabetes in terms of clinical course and com-
plication rates and should be treated as such
during Ramadan.
Newer Technologies
Newer technologies relevant and exclusive to
patients with T1 diabetes has been discussed in
the section ‘‘Type 1 diabetes: Education and
Management’’. The use of FSL-CGM in high-risk
T1/T2 diabetes patients (n = 169) has been
shown to aid optimization of glycaemic control
without compromising weight, blood pressure
or renal function [154]. The authors of this
study reported a higher incidence of hypogly-
caemia. Similarly, use of FSL-CGM in T2
patients with stable CHD during fasting in
Ramadan showed a significant improvement in
the HbA1c and a higher incidence of prolonged
hypoglycaemia, which was not associated with
any adverse cardiovascular effects [88]. The
limitations of these studies are that they were
not controlled, the accuracy of FSL-CGM in
fasting patients is not studied and there was no
correlation with SMBG. We conclude that FSL-
CGM may be considered in high-risk T2 dia-
betes patients who insist on fasting.
Post-Bariatric Patients
Bariatric surgery is being increasingly performed
in patients with morbid obesity and diabetes
[155]. Fasting in these patients can put them at
risk of malnutrition and dehydration. Fasting
has been shown to be well tolerated in patients
who undergo sleeve gastrectomy [156]. We
conclude that this group of patients should be
supported in fasting with adequate advice on
nutrition, hydration and medication changes.
The Elderly
The reduced physiological reserve associated
with aging can put frail elderly patients at
greater risk of fasting-associated medical com-
plications. Although elderly people with co-
morbidities are stratified in the high-risk cate-
gory, old age on its own is not considered to be
an independent risk factor for fasting.
In elderly patients with diabetes, there is an
increased prevalence of visual impairment from
retinal disease, cataracts, glaucoma; gait distur-
bances from peripheral neuropathy, previous
amputation or stroke; cardiovascular disease;
cognitive dysfunction; mood disturbances; and
sarcopenia [157]. All of these conditions can
adversely impact the ability of an elderly person
to fast safely.
Fasting can adversely affect postural control
of elderly people; this is worse in those who are
habitual fallers pre-Ramadan [158]. During
Ramadan, there is partial sleep deprivation,
which can adversely affect cognitive function,
attention and memory [159].
In the pre-Ramadan risk assessment, a base-
line assessment of functional capacity, mood
and cognition is essential to assist the decision-
making process on fasting in the elderly and for
future planning. A pre-Ramadan fasting pro-
gramme consisting of planned changes in
mealtimes and altered sleeping habits can help
the elderly adapt to the changes during Rama-
dan. Particular emphasis is to be laid on main-
taining sleep duration by going to bed early and
on avoiding unaccustomed surfaces and inade-
quate environments, such as wet surfaces and
reduced ambient lighting, to minimize the risk
of falling [158]. A review of all medications,
including hypoglycaemic agents with varying
hypoglycaemic potential, is essential.
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COVID-19 Infection—See Commentary
(https://doi.org/10.1007/s13300-020-
00887-x)
In light of the COVID-19 pandemic, individuals
from a Black, Asian and Minority Ethnic (BAME)
background and with obesity and diabetes
appear to be more at risk for adverse outcomes.
The concerns and risks raised, and in particular
how one should manage such patients intend-
ing to fast during Ramadan, are discussed in the
commentary accompanying this review.
CONCLUSIONS
Every year millions of Muslims fast, often doing
so contrary to medical advice. Many patients
admit to a do-it-yourself approach to diabetes
management during Ramadan, largely due to
under-appreciation of the risks and implications
of the rigors of fasting on their diabetes, and the
effects of antihyperglycaemic agents on their
blood glucose levels in the fasting state. Many
patients attempt to simply endure the difficulty
in controlling the blood glucose levels within a
defined time period B 30 days.
Part of the issue may also lie with the per-
ceived inability of HCPs to grasp the religious
sensitivities in relation to disease management
when it comes to Muslims [160]. Thus, to mit-
igate the above, the pre-Ramadan assessment is
crucial for the purpose of education, patient
self-empowerment, medication adjustments
and general advice, all with the aim to ensure a
safe Ramadan experience. Those in the high- to
very high-risk category should be closely sup-
ported by HCPs.
Although there is a conspicuous lack of
RCTs, there is sufficient evidence across the
different classes of agents in terms of safety and
efficacy to support the patient and the HCP
with informed decision-making. Ultimately,
Ramadan provides an excellent opportunity for
engagement between the HCP and the patient
to discuss important dietary, lifestyle and med-
ication changes, to improve their control in the
short-term during Ramadan, and in the long-
term, to prevent complications. If observants
can sustain the metabolic gains achieved by
Ramadan fasting by continuing to adhere to the
dietary discipline and behavioural changes over
longer periods post-Ramadan, then there is a
potential for long-term health dividends,
reflecting as a reduction in the risk of compli-
cations, and improvement in physical and
mental health and general well-being.
Links to resources
Ramadan and Diabetes. Diabetes UK:
https://www.diabetes.org.uk/guide-to-
diabetes/managing-your-diabetes/
ramadan.
Ramadan Rapid Review – British Islamic
Medical Association: https://britishima.
org/ramadan-rapid-review/.
Guidelines for healthcare professionals:
diabetes and Ramadan practical
guidelines. International Diabetes
Federation: https://www.idf.org/our-
activities/education/diabetes-and-
ramadan/healthcare-professionals.html.
Guidelines for people with diabetes—
International Diabetes Federation: https://
www.idf.org/our-activities/education/
diabetes-and-ramadan/people-living-
with-diabetes.html.
‘Can I fast with diabetes during
Ramadan?’. Diabetes Voice, International
Diabetes Federation: https://
diabetesvoice.org/en/caring-for-diabetes/
can-i-fast-with-diabetes-during-ramadan/.
Ramadan and Diabetes: A guide for
patients. Muslim Council Britain: http://
www.mcb.org.uk/wp-content/uploads/
2014/06/Ramadan-and-diabetes-A-guide-
for-patients-2013.pdf.
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